SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
March 10, 2026

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference March 10, 2026, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Amy Green
Mychelle Fernandez	Cheryl Andreoli	Stephen Munday	
Elyse Walk	Elizabeth Montano	Steven Robert Head	
Roberto Aiolfi	Lorena Garcia Menendez	Case McNamara	
Raphael Park			
Smita Chopade			

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the February 11, 2026 IBC Meeting.

II. ANNOUNCEMENTS

None.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

None.

IV. CONFLICT OF INTEREST

None.

V. REVIEW OF PROTOCOLS

Summary of Discussions: Summaries of each research proposal were thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

FULL COMMITTEE REVIEW

RENEWALS

1. IBC Protocol #:	**03-11-26-01, Boddy, Nick**
Title of Study:	Defining Genome Stability Mechanisms and their Regulation by SUMO and Ubiquitin
Department:	Molecular & Cellular Biology
Primary Reviewer:	Elyse Walk
Secondary Reviewer:	Roberto Aiolfi
NIH Guidelines:	III-D-2
Agents/Materials:	Lentivirus, Human cell lines.
Biosafety Level:	BSL-2

Animal work: ☐Yes ☒No
Biosafety Inspection: Inspection of MB 107 completed on 2/12/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study
The locations of the flow cytometry core and BSL-1 work need to be added.

Study Design/Project Description
A description of whether flow cytometry and microscopy samples are live/unfixed or fixed is needed.

Regulatory Assessment
Under NIH guidelines, the box for III-D-I research needs to be checked.

Risk Assessment
Flow cytometry needs to be selected.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

2. IBC Protocol #: **03-11-26-02, Saez, Enrique**
Title of Study: Genetic Basis of Metabolic Disorders
Department: Molecular & Cellular Biology
Primary Reviewer: Smita Chopade
Secondary Reviewer: Michael Bobardt
NIH Guidelines: III-D-1, III-D-2, III-D-4-a, III-E-1
Agents/Materials: Adeno-associated virus, lentivirus, Human cell lines.
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒Yes ☐No
Biosafety Inspection: Inspection of SR 212, 208B completed on 2/17/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information
Standard safety information for the use of lentivirus is needed here. The updated AUP and IACUC protocol need to be added.

Location of Study
This section needs to be updated to include all locations where work with nucleic acids is performed. Use of centrifuge needs to be updated.

Infectious Agents
Adeno-associate virus is BSL-1, this needs to be changed from BSL-2.

Vertebrate or Invertebrate Animals
Contaminated bedding and animal injection sites should be selected for up to 72 hours post infection.

Human/Non-human Primate Material
The source of agents needs to be added.

Study Design/Project Description
The use of safety cups needs to be clarified for ultracentrifugation. Clarification on the physical status of shipped viral vectors is needed.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

3. IBC Protocol #:	**03-11-26-03, Andersen, Kristian**
Title of Study:	RNA Sequencing Projects
Department:	Translational Medicine
Primary Reviewer:	Raphael Park
Secondary Reviewer:	Mychelle Fernandez
NIH Guidelines:	III-D-2
Agents/Materials:	*Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Klebsiella pneumoniae, Yersinia pestis, Mycobacterium tuberculosis*, Zika Virus, West Nile Virus, SARS-CoV-2, respiratory syncytial virus, Poliovirus, coxsackie virus A, *Mycobacterium tuberculosis,* Human cell lines, Non-human primate cell lines.
Biosafety Level:	BSL-2+
Animal work:	☐Yes ☒No
Biosafety Inspection:	Inspection of IMM 114, 215 completed on 2/11/26.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Infectious Agents
Nucleic acid samples should be removed from the table.

Toxins
Tetanus toxin should be added if it is still included in this study.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

4. IBC Protocol #:	**03-11-26-04, Chanda, Sumit**
Title of Study:	Restriction of Flavivirus Infection by Human Host Factors or Chemical Modulators
Department:	Immunology & Microbiology
Primary Reviewer:	Roberto Aiolfi
Secondary Reviewer:	Cheryl Andreoli
NIH Guidelines:	III-D-1, III-D-2, III-E-1
Agents/Materials:	West Nile Virus, CHIKV 181/clone 25 strain (attenuated live vaccine strain), DENV-1,2,3, zika virus, Vaccinia virus, Dengue, Human cell lines, Non-human primate cell lines.
Biosafety Level:	BSL-2+

Animal work: ☐Yes ☒No
Biosafety Inspection: Inspection of IMM 212, Calibr B26 completed on 2/12/26.
Training: Pending training.

The following action items were identified as needing to be updated on the protocol:

General Information
Specification that West Nile Virus is the BSL2+ agent is needed here.

Location of Study
The location of BSL-1 work needs to be added.

Study Design/Project Description
Detailed information regarding the quality control of CHIKV 181/clone 25 strain (e.g. maintenance of the attenuated live vaccine strain) is needed.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

5. IBC Protocol #: **03-11-26-05, Chanda, Sumit**
Title of Study: Host genetic factors and small molecules that modulate infection and replication of respiratory viruses
Department: Immunology & Microbiology
Primary Reviewer: Michael Bobardt
Secondary Reviewer: Smita Chopade
NIH Guidelines: III-D-1, III-D-7-b, III-E-1
Agents/Materials: Influenza Virus, Measles virus, Human cell lines, Non-human primate cell lines.
Biosafety Level: BSL-2+, ABSL-2
Animal work: ☒Yes ☐No
Biosafety Inspection: Inspection of IMM 212, Calibr B26 completed on 2/12/26.
Training: Pending training.

The following action items were identified as needing to be updated on the protocol:

General Information
The five-day quarantine from birds and waterfowl needs to be added to the containment assessment. Information regarding the requirement for handling HPAIV and other flu viruses on separate days is needed. The description of the research project needs to be narrowed for a lay audience. Clarification that H5N1 work is performed in the ABSL-3, not BSL-3 is needed.

Infectious Agents
Human cell lines need to be changed to RG2.

Risk Assessment
Transmission of measles virus via aerosols needs to be added. The table needs to be completed to include all biohazardous materials.

Exposure Control

ABSL3 should be checked.
Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

6. IBC Protocol #:	**03-11-26-06, Williamson, James**
Title of Study:	Assembly of Large Macro Molecular Complexes
Department:	ISCB
Primary Reviewer:	Cheryl Andreoli
Secondary Reviewer:	Raphael Park
NIH Guidelines:	III-D-1, III-D-2, III-E-1
Agents/Materials:	Lentivirus, Human cell lines.
Biosafety Level:	BSL-2
Animal work:	☐Yes ☒No
Biosafety Inspection:	Inspection of SR 312, 308, BCC 110 completed on 2/17/26.
Training:	Pending training.

The following action items were identified as needing to be updated on the protocol:

Human/Non-human Primate Material
The addition of adenovirus as the potential pathogen for 293 cells is needed. The mouse cell line can be removed from here.

Study Design/Project Description
Detailed information regarding the use of cell lines is needed.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

BIOSAFETY REVIEW

1. IBC Protocol #:	**11-13-24-01, Irvine, Darrell**
Title of Study:	Immune engineering studies
Department:	Immunology & Microbiology
NIH Guidelines:	III-D-1, III-D-2, III-D-4, III-E-1, III-F-1
Agents/Materials:	Lentivirus, Adenovirus, Plasmodium falciparum, recombinant Vaccinia Virus (VV) Western Reserve (WR) strain (VACV), Human cell lines, Non-human primate cell lines, Non-human primate primary cells.
Biosafety Level:	BSL-2, ABSL-2
Animal work:	☒Yes ☐No
Training:	Training verified and on record.
REVIEW OUTCOME:	**Approved.**

VI. ADJOURNMENT
The next scheduled IBC meeting is **Wednesday, April 8, 2026,** via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled. Members will be notified via e-mail of meeting cancellations one week before the scheduled meeting.